This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Phenobarbitone 30 mg|
|Indication||Treatment of seizures, convulsions, idiopathic epilepsy and status epilepticus in dogs.|
|Contraindications||Severe hepatic or renal impairment.|
|Actions||A long acting barbiturate with sedative, hypnotic and anticonvulsant properties.|
|Precautions||Should be used cautiously during pregnancy because pregnant animals are more sensitive or responsive to depressant effects than nonpregnant animals.Exposure during prenatal growth can induce permanent changes in sexual development.Reduced dose rate should be used in geriatric animals with severe respiratory insufficiency.Disposal Dispose of empty container by wrapping with paper and putting in garbage.|
|Dosage and Administration||Dogs. 2 to 8 mg/kg. 30 mg tablets. ½ to 2 tablets/7.5 kg bodyweight. 100 mg tablets. ¼ to 1 tablet/12.5 kg bodyweight. Administer once daily or in divided doses every twelve hours.Medication should be consistently given at the same times each day. Divide the tablet to obtain the required dose. Use the minimum dose necessary to control the condition.After initiation of treatment, dosing should continue unchanged for two to three weeks (i.e. seven times the half-life of phenobarbitone in dogs) in order to achieve steady state concentration (Css). Serum should be monitored and dosage adjusted in order to achieve Css within 20 to 40 microgram/mL (86 to 172 micromol/mL) and a good clinical response. If indicated, taper the dose over one to two weeks. Avoid abrupt withdrawal. Tolerance to phenobarbitone may develop after prolonged use, therefore dosage may need to be increased as required.|
|Storage||Store below 30°C (room temperature). Protect from light.|
|MSDS (external link)||Phenomav Tablets 30mg MSDS|
|Label (external link)||Phenomav Tablets 30mg Label|
|Manufacturer||Mavlab Pty Ltd|